Subclinical disease activity in systemic lupus erythematosus: Immunoinflammatory markers do not normalize in clinical remission

被引:0
|
作者
Wais, T
Fierz, W
Stoll, T
Villiger, PM
机构
[1] Univ Hosp Bern, Dept Rheumatol & Clin Allergol, CH-3010 Bern, Switzerland
[2] Kantonsspital, Inst Clin Immunol & Microbiol, St Gallen, Switzerland
[3] AarReha Schinznach, Schinznach, Switzerland
关键词
cytokines; cytokine antagonists; disease activity; systemic lupus erythematosus; BILAG; adhesion molecules;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To correlate various laboratory measures in systemic lupus erythematosus (SLE) with the British Isles Lupus Assessment Group (BILAG) disease activity index, to search for organ-specific laboratory patterns and to compare with a control population. Methods. A cohort of 57 Caucasian outpatients fulfilling the American College of Rheumatology criteria for SLE and a control population of 17 patients admitted for coronarography were examined. Disease activity was assessed with BILAG index. Plasma samples were investigated for sCD44, interleukin 6 (IL-6), IL-10, IL-12, tumor necrosis factor-alpha (TNF-alpha), soluble TNF receptor-55 (sTNFR-55), sTNFR-75, IL-1-receptor antagonist, soluble intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM), E-selectin, and neopterin as well as for C3, C4, dsDNA, and other conventional indicators. Results. Thirty-nine patients had inactive disease (total BILAG score less than or equal to 5), 18 patients had active SLE. Surprisingly, except for C-reactive protein (p < 0.001), no statistically significant difference of the laboratory indicators was found between patients with active and those with inactive SLE. However, there was a significant difference between SLE patients and controls for sTNFR-75 (p < 0.008). We found significant correlations between laboratory markers and some BILAG organ system scores, such as between IL-1ra and the musculoskeletal score (p < 0.003) and between sTNFR-55/sTNFR-75 and renal BILAG (p < 0.001, p < 0.004, respectively). Significant nonparametric correlations were revealed between C3 and C4 (p < 0.0001), and between sTNFR-75 and dsDNA, neopterin, sVCAM, sICAM and sTNFR-55 concentrations (p < 0.0001 for all), and between sTNFR-75 and IL-1ra (p < 0.006). Conclusion. Patients with SLE in clinical remission show ongoing systemic immunoinflammatory activity measured with a variety of cytokines, adhesion molecules, and other inflammatory markers. This indicates that laboratory measures may provide qualitatively different additional information to validated disease activity indexes such as the BILAG. Different laboratory markers correlate with disease activity in different organ systems. This suggests differences in pathogenic mechanisms in SLE depending on the organ system involved.
引用
收藏
页码:2133 / 2139
页数:7
相关论文
共 50 条
  • [21] Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value
    Hammad, Samar M. M.
    Harden, Olivia C.
    Wilson, Dulaney A.
    Twal, Waleed O.
    Nietert, Paul J.
    Oates, Jim C.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [22] ZAP70+B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis.
    Gremese, Elisa
    Tolusso, Barbara
    Messuti, Laura
    Nowik, Marcin
    Canestri, Silvia
    Petricca, Luca
    Gigante, Maria Rita
    Ferraccioli, Gianfranco
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S292 - S292
  • [23] Prospective Comparison of Remission and Lupus Low Disease Activity State - Effect on Disease Outcomes in Systemic Lupus Erythematosus
    Golder, Vera
    Kandane-Rathnayake, Rangi
    Huq, Molla
    Louthrenoo, Worawit
    Luo, Shue-Fen
    Wu, Yeong-Jian
    Lateef, Aisha
    Sockalingam, Sargunan
    Morton, Susan
    Navarra, Sandra V.
    Zamora, Leonid
    Hamijoyo, Laniyati
    Katsumata, Yasuhiro
    Harigai, Masayoshi
    Chan, Madelynn
    O'Neill, Scan
    Goldblatt, Fiona
    Lau, Chak Sing
    Li, Zhan-Guo
    Hoi, Alberta Y.
    Nikpour, Mandana
    Morand, Eric
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] Subclinical atherosclerosis in systemic lupus erythematosus patients: relation to disease activity and damage index
    Fadda, S.
    Nassar, H.
    Gamal, S. M.
    Al-azizi, H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 : 66 - 66
  • [25] PROLONGED CLINICAL REMISSION AND LOW DISEASE ACTIVITY STATUSES ARE ASSOCIATED WITH BETTER QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Poomsalood, Nareerat
    Chaiamnuay, Sumapa
    Narongroeknawin, Pongthorn
    Asavatanabodee, Paijit
    Pakchotanon, Rattapol
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1703 - 1704
  • [26] Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus
    Poomsalood, N.
    Narongroeknawin, P.
    Chaiamnuay, S.
    Asavatanabodee, P.
    Pakchotanon, R.
    LUPUS, 2019, 28 (10) : 1189 - 1196
  • [27] Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
    Jorge, April
    Lertratanakul, Apinya
    Lee, Julia
    Pearce, William
    McPherson, David
    Thompson, Trina
    Barinas-Mitchell, Emma
    Ramsey-Goldman, Rosalind
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [28] Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
    Jorge, April
    Lertratanakul, Apinya
    Lee, Jungwha
    Pearce, William
    McPherson, David
    Thompson, Trina
    Barinas-Mitchell, Emma
    Ramsey-Goldman, Rosalind
    ARTHRITIS CARE & RESEARCH, 2017, 69 (01) : 5 - 11
  • [29] Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients
    Reategui-Sokolova, C.
    Rodriguez-Bellido, Z.
    Gamboa-Cardenas, R. V.
    Medina, M.
    Zevallos, F.
    Pimentel-Quiroz, V. R.
    Elera-Fitzcarrald, C.
    Cucho-Venegas, M.
    Pastor-Asurza, C. A.
    Perich-Campos, R.
    Alarcon, G. S.
    Ugarte-Gil, M. F.
    LUPUS, 2019, 28 (11) : 1344 - 1349
  • [30] High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus
    Formiga, F
    Moga, I
    Pac, M
    Mitjavila, F
    Rivera, A
    Pujol, R
    RHEUMATOLOGY, 1999, 38 (08) : 724 - 727